Abstracts tagged "gout"

Abstract Number: L08 • ACR Convergence 2020
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Thomas MacDonald¹, Isla Mackenzie¹, George Nuki² and Ian Ford³, ¹University of Dundee, Dundee, Scotland, United Kingdom, ²University of Edinburgh, Edinburgh, Scotland, United Kingdom, ³University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…
Abstract Number: 0653 • ACR Convergence 2020
Nutrient Content of Gout Flare Trigger Foods
Tanya Major¹, Ruth Topless¹, Elsa Sanchez-Lopez², Jennie Harré Hindmarsh³, Lisa Stamp⁴, Nicola Dalbeth⁵, Monica Guma⁶, Robert Terkeltaub⁷ and Tony Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²University of California San Diego, San Diego, CA, ³Ngāti Porou Hauora, Te Puia Springs, New Zealand, ⁴University of Otago Christchurch, Christchurch, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of California San Diego, La Jolla, CA, ⁷VA/UCSD, San Diego, CA
Background/Purpose: A wide variety of foods are reported by patients to be triggers of gout flares. Some of these foods have been associated with serum…
Abstract Number: 0673 • ACR Convergence 2020
Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure
Brian LaMoreaux¹, Megan Francis-Sedlak¹, Scott Neville² and Robert Holt¹, ¹Horizon Therapeutics plc, Lake Forest, IL, ²Foot and Ankle Center, Mooresville, IN
Background/Purpose: Gout can cause uric acid deposition in joints, soft tissues, and organs (1) and is associated with heart disease, kidney disease, hypertension, hyperlipidemia, diabetes,…
Abstract Number: 0950 • ACR Convergence 2020
The Association Between Gout and Cardiovascular Disease Outcomes: Assessment and Recalibration of Individual-level Primary Prevention Risk Prediction Equations in Approximately 450,000 New Zealanders
Ken Cai¹, Billy Wu², Nicola Dalbeth², Rod Jackson² and Katrina Poppe², ¹University of Auckland, Sydney, New South Wales, Australia, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Some studies have reported that gout is an independent risk factor for cardiovascular disease (CVD). Individual-level cardiovascular risk prediction equations have been developed and…
Abstract Number: 0654 • ACR Convergence 2020
The Effects of Dietary Macronutrients on Serum Urate: A Secondary Analysis of the OmniHeart Trial
Matthew Belanger¹, Christina Wee¹, Kenneth Mukamal¹, Edgar Miller², Frank Sacks³, Lawrence Appel², Robert Shmerling⁴, Hyon Choi⁵ and Stephen Juraschek¹, ¹Beth Israel Deaconess Medical Center/Harvard Medical School, Division of General Medicine, Boston, MA, ²Johns Hopkins University, School of Medicine, Department of Medicine, Division of General Internal Medicine, Baltimore, MD, ³Harvard T. H. Chan School of Public Health, Department of Nutrition, Boston, MA, ⁴Beth Israel Deaconess Medical Center/Harvard Medical School, Division of Rheumatology, Mashpee, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Diet is a significant determinant of hyperuricemia and risk for gout. Dietary recommendations to prevent gout emphasize reducing purine intake; however, low-purine diets are…
Abstract Number: 0674 • ACR Convergence 2020
Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan
Ruriko Koto¹, Akihiro Nakajima¹, Hideki Horiuchi¹ and Hisashi Yamanaka², ¹Teijin Pharma Limited, Tokyo, Japan, ²Sanno Medical Center, Tokyo, Japan
Background/Purpose: Japanese guidelines for managing gout and hyperuricemia recommend the initiation of urate-lowering therapy (ULT) to prevent gouty arthritis in subjects having asymptomatic hyperuricemia with…
Abstract Number: 0951 • ACR Convergence 2020
The Comparative Effect of Exposure to Various Risk Factors on the Risk of Hyperuricaemia: Diet Has a Weak Causal Effect
Ruth Topless¹, Tanya Major¹, Jose Florez², Joel Hirschhorn³, Murray Cadzow¹, Nicola Dalbeth⁴, Lisa Stamp⁵, Phillip Wilcox¹, Richard Reynolds⁶, Joanne Cole² and Tony Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²Massachusetts General Hospital, Boston, ³Harvard Medical School, Boston, ⁴University of Auckland, Auckland, New Zealand, ⁵University of Otago Christchurch, Christchurch, New Zealand, ⁶University of Alabama Birmingham, Birmingham
Background/Purpose: Prevention of hyperuricaemia (HU) is critical to the prevention of gout. Therefore, understanding the causal relationships and relative contributions of various risk factors to…
Abstract Number: 0655 • ACR Convergence 2020
Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial
Kristian Zobbe¹, Robin Christensen², Sabrina Mai Nielsen³, Lisa Stamp⁴, Marius Henriksen⁵, Anders Føhrby Overgaard⁶, Lene Dreyer⁷, Filip Krag Knop⁸, Jasvinder Singh⁹, Michael Doherty¹⁰, Pascal Richette¹¹, Arne Astrup¹², Karen Ellegaard¹, Else Marie Bartels¹³, Mikael Boesen¹⁴, Henrik Rindel Gudbergsen¹⁵, Henning Bliddal¹⁵ and Lars Erik Kristensen¹⁶, ¹The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, Denmark, ²Musculoskeletal Statistics Unit, The Parker Institute/Odense University Hospital, Copenhagen F, Denmark, ³The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, Frederiksberg, Denmark, ⁴University of Otago Christchurch, Christchurch, New Zealand, ⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, ⁶The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Sorø, ⁷Department of Rheumatology, Aalborg UnIversity Hospital, Aalborg, Denmark, ⁸Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, Copenhagen, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Academic Rheumatology, School of Medicine, University of Nottingham, Nottingham UK, Nottingham, United Kingdom, ¹¹Department of Rheumatology, Lariboisière Hospital, Paris, France, ¹²Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark, ¹³Department of Neurology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Frederiksberg, Denmark, Copenhagen, Denmark, ¹⁴Department of Radiology Copenhagen University hospital Bispebjerg and Frederiksberg; The Parker Institute, Copenhagen, Denmark, ¹⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Frederiksberg, Denmark, ¹⁶The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Despite scarce evidence regarding the effects of weight loss in gout1, international guidelines recommend dietary advice and weight loss as a core management strategy…
Abstract Number: 0676 • ACR Convergence 2020
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care
Joshua Gavin¹, Yashswee KC², Evan Dombrosky³, Nehal Shah⁴ and Youssef Roman⁴, ¹Virginia Commonwealth University School of Medicine, Richmond, ²Virginia Commonwealth University School of Medicine, Henrico, VA, ³Virginia Commonwealth University School of Medicine, Glen Allen, VA, ⁴Virginia Commonwealth University School of Medicine, Richmond, VA
Background/Purpose: The management of gout is heterogeneous across specialties and clinical settings. Gout has been demonstrated to be one of the most poorly managed conditions…
Abstract Number: 0952 • ACR Convergence 2020
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Puja Khanna¹, Dinesh Khanna¹, Gary Cutter², Jeffrey Foster², Joshua Melnick³, Sara Jaafar¹, Stephanie Biggers², AKM Rahman², Hui-Chen Kuo², Michelle Feese² and Kenneth Saag⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham (UAB), Vestavia Hills, AL, ⁴University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of…
Abstract Number: 0656 • ACR Convergence 2020
A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis
Philip Robinson¹, Nicola Dalbeth², Chris Frampton³, Tony Merriman³, Amanda Phipps-Green³ and Peter Donovan⁴, ¹University of Queensland, Herston, Queensland, Australia, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴Royal Brisbane & Women's Hospital, HERSTON, Queensland, Australia
Background/Purpose: Intake of sugar is associated with increased incident gout. Sugar taxes have been effective at reducing the intake of sugar in several jurisdictions. We…
Abstract Number: 0677 • ACR Convergence 2020
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
John Botson¹, Paul Peloso², Katie Obermeyer³, Brian LaMoreaux³, Lin Zhao³, Michael Weinblatt⁴ and Jeff Peterson⁵, ¹Orthopedic Physicians Alaska, Anchorage, AK, ²Horizon Therapeutics plc, Gurnee, IL, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Western Washington Medical Group Arthritis Clinic, Bothell, WA
Background/Purpose: Consistent, though limited, published data suggests that methotrexate (MTX) improves treatment response in patients treated with pegloticase for uncontrolled (refractory) gout. Recent case series1-3…
Abstract Number: 0953 • ACR Convergence 2020
Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout
Jacob Wozniak¹, Ru Bryan², David Gonzalez³ and Robert Terkeltaub⁴, ¹UC San Diego, San Diego, CA, ²UCSD, San Diego, CA, ³UC San Diego, San Diego, CO, ⁴VA Medical Center/UC San Diego, San Diego, CA
Background/Purpose: In gout, long-term xanthine oxidase inhibitor treat to target urate lowering therapy (XOIT2T) markedly reduces flares and synovitis, despite delayed resolution of tissue crystal…
Abstract Number: 0063 • ACR Convergence 2020
Novel Repurposed Drugs Against Joint Inflammation Reveal Potential Use for Gout Treatment: An In Silico, In Vitro and Clinical Study
Eloi Franco-Trepat¹, Ana Alonso-Pérez¹, Maria Guillán-Fresco¹, Miriam López-Fagundez¹, Andrés Pazos-Pérez¹, Ana Lois Iglesias², Susana Belén Bravo³, Alberto Jorge-Mora¹, JJ Gómez-Reino⁴ and Rodolfo Gómez¹, ¹IDIS-CHUS - Musculoskeletal Pathology Group, Santiago de Compostela, Spain, ²IDIS-CHUS - Musculoskeletal Pathology Group, A Coruna, Spain, ³IDIS-CHUS - Proteomics Unit, Santiago de Compostela, Galicia, Spain, ⁴IDIS-CHUS - Rheumatology Group, Santiago de Compostela, Spain
Background/Purpose: Joint inflammation is a common feature across multiple rheumatic diseases. To deal with the induction of innate immune factors, targeting therapeutic targets such as…
Abstract Number: 0657 • ACR Convergence 2020
Gout and Heart Failure in the US
Gurkipal Singh¹, Maanek Sehgal² and Alka Mithal³, ¹Stanford University, Stanford, CA, ²UCLA, Los Angeles, CA, ³ICORE, Woodside, CA
Background/Purpose: Heart failure (HF) is the eighth leading cause of death in the US, with a 38% increase in the number of deaths due to…

1
2
3
…
28
Next Page »